Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (albumin-bound) with Palbociclib and Fulvestrant in Advanced HR+/HER2- Breast Cancer
NCT06941142Phase 1Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of nab-sirolimus in Hormone-Receptor-Positive Breast Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Adverse Events at 2 years, Dose-Limiting Toxicities at 1 year and 3 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nab-sirolimus
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT06941142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941142.